Clinical Trial

A Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid Arthritis

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This Phase 2b, multicenter, double-blind, placebo-controlled, randomized withdrawal study is designed to assess the efficacy and safety of IMVT-1402 in adult participants with active, difficult-to-treat, anti-citrullinated protein autoantibody (ACPA) positive rheumatoid arthritis (RA).
Protocol Amendment History 14 amendments
This ClinicalTrials.gov record has been amended 14 times since 2024-12-24; most recent amendment 2026-04-21.
Status change: Recruiting → Active, Not Recruiting 2025-12-05
Status change: Not Yet Recruiting → Recruiting 2025-02-01
Trial Details
NCT Number NCT06754462
Lead Sponsor Immunovant Sciences GmbH
Conditions Rheumatoid Arthritis
Enrollment 120 participants
Start Date 2025-01-10
Primary Completion 2027-09 (estimated)
Study Completion 2027-09 (estimated)
Updated on ClinicalTrials.gov 2026-04-22